Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England journal of medicine, 2017-05, Vol.376 (18), p.1713-1722 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615664 ;PMID: 28304224Full text available |
2 |
Material Type: Article
|
![]() |
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trialThe Lancet (British edition), 2017-04, Vol.389 (10077), p.1399-1409 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 8, 2017 ;2017. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)30069-7 ;PMID: 28237263Full text available |
3 |
Material Type: Article
|
![]() |
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitusNature reviews. Endocrinology, 2020-10, Vol.16 (10), p.556-577 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;Springer Nature Limited 2020. ;ISSN: 1759-5029 ;ISSN: 1759-5037 ;EISSN: 1759-5037 ;DOI: 10.1038/s41574-020-0392-2 ;PMID: 32855502Full text available |
4 |
Material Type: Article
|
![]() |
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes MellitusDrugs (New York, N.Y.), 2015-01, Vol.75 (1), p.33-59 [Peer Reviewed Journal]Springer International Publishing Switzerland 2014 ;Copyright Springer Science & Business Media Jan 2015 ;ISSN: 0012-6667 ;ISSN: 1179-1950 ;EISSN: 1179-1950 ;DOI: 10.1007/s40265-014-0337-y ;PMID: 25488697Full text available |
5 |
Material Type: Article
|
![]() |
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular diseaseDiabetes & metabolism, 2018-12, Vol.44 (6), p.457-464 [Peer Reviewed Journal]2018 Elsevier Masson SAS ;Copyright © 2018 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2018.09.005 ;PMID: 30266577Full text available |
6 |
Material Type: Article
|
![]() |
Metformin and COVID-19: From cellular mechanisms to reduced mortalityDiabetes & metabolism, 2020-11, Vol.46 (6), p.423-426 [Peer Reviewed Journal]2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.07.006 ;PMID: 32750451Full text available |
7 |
Material Type: Article
|
![]() |
Weight management in type 2 diabetes: current and emerging approaches to treatmentDiabetes care, 2015-06, Vol.38 (6), p.1161-1172 [Peer Reviewed Journal]2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. ;Copyright American Diabetes Association Jun 2015 ;ISSN: 0149-5992 ;ISSN: 1935-5548 ;EISSN: 1935-5548 ;DOI: 10.2337/dc14-1630 ;PMID: 25998297 ;CODEN: DICAD2Full text available |
8 |
Material Type: Article
|
![]() |
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsThe New England journal of medicine, 2010-09, Vol.363 (10), p.905-917 [Peer Reviewed Journal]Copyright © 2010 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1003114 ;PMID: 20818901 ;CODEN: NEJMAGFull text available |
9 |
Material Type: Article
|
![]() |
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular EventsThe New England journal of medicine, 2010-04, Vol.362 (16), p.1477-1490 [Peer Reviewed Journal]Copyright © 2010 Massachusetts Medical Society. All rights reserved. ;2010 Massachusetts Medical Society ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1001121 ;PMID: 20228403 ;CODEN: NEJMAGFull text available |
10 |
Material Type: Article
|
![]() |
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 InhibitorClinical pharmacokinetics, 2014-03, Vol.53 (3), p.213-225 [Peer Reviewed Journal]The Author(s) 2014 ;2015 INIST-CNRS ;Copyright Wolters Kluwer Health Adis International Mar 2014 ;ISSN: 0312-5963 ;ISSN: 1179-1926 ;EISSN: 1179-1926 ;DOI: 10.1007/s40262-013-0126-x ;PMID: 24430725 ;CODEN: CPKNDHFull text available |
11 |
Material Type: Article
|
![]() |
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonistsDiabetes & metabolism, 2022-11, Vol.48 (6), p.101390-101390, Article 101390 [Peer Reviewed Journal]2022 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2022.101390 ;PMID: 36170946Full text available |
12 |
Material Type: Article
|
![]() |
Lower limb amputations: protection with GLP-1 receptor agonists rather than increased risk with SGLT2 inhibitors?Diabetes & metabolism, 2022-03, Vol.48 (2), p.101325-101325, Article 101325 [Peer Reviewed Journal]2022 Elsevier Masson SAS ;Copyright © 2022 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2022.101325 ;PMID: 35121148Full text available |
13 |
Material Type: Article
|
![]() |
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular EventsThe New England journal of medicine, 2010-04, Vol.362 (16), p.1463-1476 [Peer Reviewed Journal]Copyright © 2010 Massachusetts Medical Society. All rights reserved. ;2010 Massachusetts Medical Society ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1001122 ;PMID: 20228402 ;CODEN: NEJMAGFull text available |
14 |
Material Type: Article
|
![]() |
DPP-4 inhibition and COVID-19: From initial concerns to recent expectationsDiabetes & metabolism, 2021-03, Vol.47 (2), p.101213-101213, Article 101213 [Peer Reviewed Journal]2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.11.005 ;PMID: 33249199Full text available |
15 |
Material Type: Article
|
![]() |
Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney DiseaseClinical pharmacokinetics, 2020-08, Vol.59 (8), p.981-994 [Peer Reviewed Journal]Springer Nature Switzerland AG 2020 ;Copyright Springer Nature B.V. Aug 2020 ;ISSN: 0312-5963 ;ISSN: 1179-1926 ;EISSN: 1179-1926 ;DOI: 10.1007/s40262-020-00885-z ;PMID: 32201911Full text available |
16 |
Material Type: Article
|
![]() |
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studiesDiabetes & metabolism, 2021-11, Vol.47 (6), p.101220-101220, Article 101220 [Peer Reviewed Journal]2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;2020 Elsevier Masson SAS. All rights reserved. 2020 Elsevier Masson SAS ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.101220 ;PMID: 33359486Full text available |
17 |
Material Type: Article
|
![]() |
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trialsDiabetes & metabolism, 2020-06, Vol.46 (3), p.186-196 [Peer Reviewed Journal]2020 Elsevier Masson SAS ;Copyright © 2020 Elsevier Masson SAS. All rights reserved. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2020.01.002 ;PMID: 32007623Full text available |
18 |
Material Type: Article
|
![]() |
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose controlDiabetes & metabolism, 2015-06, Vol.41 (3), p.183-194 [Peer Reviewed Journal]2015 ;Copyright © 2015. Published by Elsevier Masson SAS. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2015.02.003 ;PMID: 25794703Full text available |
19 |
Material Type: Article
|
![]() |
When therapeutic drugs lead to diabetesDiabetologia, 2022-05, Vol.65 (5), p.751-762 [Peer Reviewed Journal]The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 ;2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. ;The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0012-186X ;ISSN: 1432-0428 ;EISSN: 1432-0428 ;DOI: 10.1007/s00125-022-05666-w ;PMID: 35244742Full text available |
20 |
Material Type: Article
|
![]() |
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative reviewDiabetes & metabolism, 2024-03, Vol.50 (2), p.101508-101508, Article 101508 [Peer Reviewed Journal]2023 ;Copyright © 2023. Published by Elsevier Masson SAS. ;ISSN: 1262-3636 ;ISSN: 1878-1780 ;EISSN: 1878-1780 ;DOI: 10.1016/j.diabet.2023.101508 ;PMID: 38158077Full text available |